Article, see p 891 I n his book When Bad Things Happen to Good People, Harold Kushner 1 explores explanations for human pain and suffering. He notes that although many of the afflictions of the human condition are beyond our understanding, none of us is exempt from the common experience. Despite the original publication of this thesis more than 35 years ago, we can draw parallels to the patient experience with mechanically assisted circulation. The underlying mechanism and management of several morbid and mortal left ventricular assist device (LVAD) complications are beyond contemporary understanding but are sufficiently frequent to be considered common. The article by Soliman et al 2 in this issue of Circulation adds clarity to the question why VAD things happen to good people by defining preoperative risk factors that predispose patients to the development of right-sided heart failure after implantation of a left-sided mechanical blood pump.
EDITORIAL ciency, and VAD management strategies. INTERMACS has developed a meaningful framework to diagnose RV dysfunction and to stratify its severity ( Figure) . 4 Patients with clinical evidence of RV failure requiring prolonged inotropic support, inhaled pulmonary vasodilators, or an RV assist device have statistically worse survival outcomes.
An ounce of prevention is worth a pound of cure. The challenge of post-LVAD RV failure has been the development of robust predictive models to guide patient and physician decision making. Retrospective analyses of clinical trial databases and single-center experiences have been used to develop multivariable models. Although the ability of these models to predict RV failure is superior to that of individual risk factors, their accuracy when tested in new patient cohorts has been modest. 5 Soliman and colleagues 2 use patient-level data from the EUROMACS registry (European Registry for Patients With Mechanical Circulatory Support) linked to common definitions of adverse events and outcomes to derive and test a new clinical model for the preoperative prediction of right-sided heart failure after continuousflow LVAD placement. The investigators retrospectively analyzed 2988 patients treated with a primary LVAD and randomly stratified them into derivation (n=2000) and validation (n=988) cohorts. Preoperative predictors (n=82), including demographics, clinical variables, comorbidities, medications, echocardiographic factors, hemodynamic parameters, and laboratory values, as well as cardiopulmonary bypass time, were entered into a univariate logistic regression model and retained for inclusion in a multivariable model if marginally significant. The final model was constructed from variables with standard statistical significance. With the use of INTERMACS definitions, the overall incidence of rightsided heart failure in this cohort was 22% primarily on the basis of the need for prolonged postoperative inotropic support. Smaller numbers of patients required a mechanical RV support device or prolonged administration of nitric oxide inhalation therapy. Five variables were associated with early postoperative RV failure: INTERMACS class, use of multiple intravenous inotropic agents, qualitative determination of severe RV dysfunction on echocardiography, a right atrial/pulmonary capillary wedge pressure that exceeded 0.54, and hemoglobin. These variables were used to create a numeric score to predict right heart failure (range, 0-9.5). When the EUROMACS right-sided heart failure scoring system was applied to both the derivation and validation cohorts, the model stratified risk better than previously published models. Inclusion of cardiopulmonary bypass time >100 minutes did not improve the predictive accuracy of the model.
Although the EUROMACS right-sided heart failure score appears to be an important addition in the toolbox of LVAD clinicians, thoughtful application is necessary. For example, the relatively young patient age of this cohort and the small number of patients with high EUROMACS right-sided heart failure risk scores raise the possibility that predictive accuracy may vary when the score is applied to other patient cohorts. The EUROMACS Investigators have recently published that women in this registry have a nearly 4-fold higher risk of right-sided heart failure after VAD implantation, 6 yet the cohort on which this right-sided heart failure score is derived is made up of only 18% women. The accuracy of this right-sided heart failure score and its importance for women require further testing. Finally, because this study evaluated only perioperative RV failure, its applicability to the diagnosis of late right-sided heart failure should not be assumed.
One of the challenges in the use of risk scores is clinical utility. In the end, the clinician is left using imperfect tools to counsel patients and families about the risks and benefits of high-risk interventions. Although RV failure after LVAD implantation is associated with increased morbidity and mortality, the vast majority of patients ultimately have good outcomes and a survival superior to that expected with advanced heart failure. The savvy clinician will continue to view risk modeling in the context of other data inputs, patient preference 
